Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
SoftBank Shares Fall as Oracle Flags Stargate Data Center Delay Risk 
Apple Extends Qualcomm Patent Licensing Deal 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh 
Trump, Xi Focus on Trade and AI at White House Summit 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Add as a preferred source on Google
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
